Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Bioavailability of Tebipenem (SPR994) Crushed Tablet Formulation Administered by Nasogastric Tube in Healthy Subjects

NCT05296382 is registered in ClinicalTrials.gov with Hartford Hospital as lead sponsor.

NCT NCT05296382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05296382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Bioavailability of Tebipenem (SPR994) Crushed Tablet Formulation Administered by Nasogastric Tube in Healthy Subjects
Lead sponsor
Hartford Hospital
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2022
Completion date
December 23, 2022
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relative bioavailability